知镜 Cognispect · 医学文献与研究工作台

The biological role of CCR4 and its ligands CCL17 and CCL22 in atopic dermatitis: therapeutic implications and future directions.

Dahabreh D, Patel D, Del Duca E, Corriden R, Brockstedt DG, Guttman-Yassky E.
Expert opinion on therapeutic targets · 2026-06-26 · PMID 42348752

文献摘要

Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disorder driven by Th2-related cytokines, including interleukin-4 (IL-4) and IL-13. Recent single-cell sequencing and proteomic studies have demonstrated that sustained immune activity can persist even after treatment with the anti-IL-4 receptor alpha antibody dupilumab. Thus, targeting C-C chemokine receptor 4 (CCR4), which is highly expressed by Th2 cells and drives their migration into the inflamed tissues such as skin in response CCL17 (TARC) and CCL22 (MDC), could be a promising therapeutic approach for the treatment of AD. Areas covered This review summarizes: 1) the role of CCR4 and its primary endogenous ligands CCL17 and CCL22 in AD pathobiology; 2) the molecular pharmacology and associated signaling pathways of CCR4; and 3) the current landscape of CCR4 inhibitors, including key challenges in their discovery/development. The implications of CCR4 pharmacology in the development of new therapeutic agents are also discussed. Expert opinion New insights into the function and molecular pharmacology of CCR4 have informed the discovery of molecules that target CCR4 directly (e.g. small-molecule allosteric inhibitors) as well as ones that target the CCL17/CCL22/CCR4 signaling axis broadly (e.g. neutraligands). Ongoing efforts to develop therapies targeting this pathway may yield new treatments for AD.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。